<DOC>
	<DOCNO>NCT00622466</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving sorafenib together paclitaxel may kill tumor cell . PURPOSE : This phase II trial study side effect give sorafenib together paclitaxel well work treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Sorafenib Paclitaxel Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate efficacy sorafenib tosylate paclitaxel measure tumor response , define RECIST criterion , patient metastatic , HER2-negative breast cancer . Secondary - To evaluate time disease progression patient treat regimen . - To evaluate six-month progression-free survival patient treat regimen . - To evaluate time treatment failure patient treat regimen . - To evaluate clinical benefit rate ( tumor response stable disease ) 24 week patient treated regimen . - To evaluate duration response patient treat regimen . - To evaluate tolerability regimen patient . - To examine relationship gene expression tissue/serum protein marker , available , related response therapy focus growth factor receptor pathway . OUTLINE : This multicenter study . Patients receive oral sorafenib tosylate twice daily day 1-28 paclitaxel IV 1 hour day 1 , 8 , 15 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically* confirm breast cancer Stage IV ( metastatic ) disease Radiographic evidence metastasis NOTE : *Histological confirmation actual metastasis require . Measurable disease RECIST criterion define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ( i.e. , physical examination , CT scan , MRI , xray ) ≥ 10 mm spiral CT scan No prior radiotherapy unless growth document follow radiotherapy Primary tumor metastatic tumor HER2negative , define follow : Immunohistochemistry 0 1+ OR equivalent , automate quantitative assay use HER2 fluorescent situ hybridization ( FISH ) assay negative define HER2 : chromosome 17 centromeric probe ratio &lt; 1.8 ( &lt; 2.2 immunohistochemistry less 3+ equivalent ) OR equivalent value negative FISH assay normalize chromosome 17 Hormonereceptor positive ( estrogen receptor [ ER ] progesterone receptor [ PgR ] positive ) disease hormone receptornegative ( ER PgRnegative ) disease Tumor block initial breast cancer primary biopsy metastatic site must available correlative study Brain metastasis allow provided patient stable completion treatment ( i.e. , surgery and/or radiotherapy ) , asymptomatic , steroid 2 consecutive stable brain scan least 4 week radiotherapy Exclusion criterion : Boneonly nonmeasurableonly disease Newly diagnose brain metastasis PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 01 Life expectancy &gt; 6 month Menopausal status specify WBC ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT transaminases ≤ 2.5 time ULN ( &lt; 5 time ULN liver involvement ) Creatinine &lt; 1.5 time ULN OR creatinine clearance &gt; 60 mL/min INR &lt; 1.5 OR PT/PTT normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception prior ( woman men ) least 3 month ( men ) study therapy Able swallow absorb oral medication Exclusion criterion : Active uncontrolled medical illness ( e.g. , active infection &gt; CTCAE grade 2 ) , include follow : HIV chronic hepatitis B C Uncontrolled diabetes NYHA class IIIV uncompensated congestive heart failure Unstable angina ( anginal symptom rest ) New onset angina ( i.e. , begin within past 3 month ) Coronary artery disease Myocardial infarction within past 6 month Cardiac ventricular arrhythmia require antiarrhythmic therapy Evidence bleed diathesis coagulopathy Pulmonary hemorrhage/bleeding event &gt; CTCAE grade 2 within 4 week first dose study drug Any hemorrhage/bleeding event &gt; CTCAE grade 3 within 4 week first study drug Thrombotic embolic event ( i.e. , cerebrovascular accident ) , include transient ischemic attack within past 6 month Hypertension control medication ≤ 150/90 mm Hg History allergic reaction attribute compound similar chemical biologic composition sorafenib tosylate Prior invasive cancer breast cancer except nonmelanoma skin cancer Chronic nonhealing wound ulcer PRIOR CONCURRENT THERAPY : No 1 prior chemotherapy regimen metastatic breast cancer ( MBC ) At least 3 week since prior hormonal therapy MBC adjuvant neoadjuvant chemotherapy More 1 year since adjuvant paclitaxel At least 4 week since major thoracic , abdominal , pelvic surgery recover At least 3 week since prior concurrent investigational drug Concurrent bisphosphonates allow Concurrent anticoagulation agent ( i.e. , warfarin heparin ) allow No anticipate need concurrent radiotherapy No concurrent Hypericum perforatum ( St. John wort ) rifampin ( rifampicin ) No concurrent antineoplastic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>HER2-negative breast cancer</keyword>
</DOC>